About the Project
Founded in 2016, Tilos Therapeutics rapidly outgrew the shared facilities at Lab Central, Cambridge MA. The new Headquarters located at Hayden Research Campus in Lexington MA, provided the square footage and was the ideal opportunity to fit out laboratory and offices specifically designed to meet their needs.
The project consisted of offices, collaborative and conference areas and Chemistry and Tissue Culture labs.
Hereva Consultants was hired as Project Manager to guide them through their first expansion, ensuring that our client’s needs were addressed, and the work stayed on target. We provided project management from planning through modifications, and into relocation and support during operational start-up.
About the Client
Tilos Therapeutics is developing antibodies for the treatment of cancer, with additional early efforts in fibrosis and autoimmune diseases. Tilos is building on decades of work by its scientific founders in understanding the role of LAP-expressing cells in immune regulation to rapidly bring anti-LAP antibodies into clinical development.
Earlier this month Tilos was purchased by Merck. Dean Li, Senior Vice President of Discovery and Translational Medicine at Merck Research Laboratories, had this to say. “Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF beta by binding to latency-associated peptide, with potential applications across a range of disease indications.”